1211541-93-3

Basic information

• Product Name: 5-Fluoro-2-Methoxy-pyridin-3-ylaMine
• Synonyms: 5-Fluoro-2-Methoxy-pyridin-3-ylaMine;5-Fluoro-2-Methoxypyridin-3-aMine
• CAS NO: 1211541-93-3
• Molecular Formula: C6H7FN2O
• Molecular Weight: 142.1309832
• Mol File: 1211541-93-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 5-Fluoro-2-Methoxy-pyridin-3-ylaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Fluoro-2-Methoxy-pyridin-3-ylaMine(1211541-93-3)
• EPA Substance Registry System: 5-Fluoro-2-Methoxy-pyridin-3-ylaMine(1211541-93-3)

Safety Data

• Hazardous Substances Data: 1211541-93-3(Hazardous Substances Data)

Usage

General Description

5-Fluoro-2-Methoxy-pyridin-3-ylaMine is a chemical compound that belongs to the class of pyridine derivatives. It is comprised of a pyridine ring with a methoxy group attached at the 2-position and a fluorine atom at the 5-position, as well as an amine group at the 3-position. 5-Fluoro-2-Methoxy-pyridin-3-ylaMine is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. Its unique structure and functional groups make it a versatile ingredient in organic synthesis, allowing for the creation of diverse compounds with potential biological activities. The compound may have applications in the development of new drugs or agrochemical products due to its potential pharmacological and pesticidal properties. Its synthesis and properties are of interest to researchers and pharmaceutical companies in the development of new chemical entities.

Upstream product

• 84476-99-3 2,5-difluoropyridine 
• 1211534-27-8 5-fluoro-2-methoxy-3-nitropyridine 
• 136888-20-5 5-fluoro-2-hydroxy-3-nitropyridine 
• 51173-05-8 5-fluoropyridin-2-ol 

Relevant articles and documents

Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases

Janus kinases (JAKs) have a key role in regulating the expression and function of relevant inflammatory cytokines involved in asthma and chronic obstructive pulmonary disease. Herein are described the design, synthesis, and pharmacological evaluation of a series of novel purinone JAK inhibitors with profiles suitable for inhaled administration. Replacement of the imidazopyridine hinge binding motif present in the initial compounds of this series with a pyridone ring resulted in the mitigation of cell cytotoxicity. Further systematic structure-activity relationship (SAR) efforts driven by structural biology studies led to the discovery of pyridone 34, a potent pan-JAK inhibitor with good selectivity, long lung retention time, low oral bioavailability, and proven efficacy in the lipopolysaccharide-induced rat model of airway inflammation by the inhaled route.

MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER

Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.

PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES

Compoundshaving the chemical structure of formula (I) are disclosed; as well as process for theirpreparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).